Windtree Therapeutics (WINT)
(Delayed Data from NSDQ)
$4.60 USD
+0.54 (13.33%)
Updated May 15, 2024 03:43 PM ET
After-Market: $4.60 0.00 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Income Statements
Fiscal Year end for Windtree Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 21 | 41 | 77 | 30 | 25 |
Income After Depreciation & Amortization | -21 | -41 | -77 | -30 | -25 |
Non-Operating Income | 0 | 1 | 0 | -2 | -2 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -20 | -41 | -78 | -33 | -27 |
Income Taxes | 0 | -1 | -10 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -20 | -39 | -68 | -33 | -27 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -20 | -39 | -68 | -33 | -27 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -17 | -21 | -32 | -30 | -25 |
Depreciation & Amortization (Cash Flow) | 3 | 20 | 45 | 0 | 0 |
Income After Depreciation & Amortization | -21 | -41 | -77 | -30 | -25 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.22 | 0.04 | 0.03 | 0.02 | 0.01 |
Diluted EPS Before Non-Recurring Items | -94.25 | -759.53 | -2,455.04 | -1,870.50 | -2,266.41 |
Diluted Net EPS (GAAP) | -94.24 | -1,119.25 | -2,455.04 | -1,870.50 | -2,266.41 |
Fiscal Year end for Windtree Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.96 | 4.69 | 6.75 | 4.19 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.96 | -4.69 | -6.75 | -4.19 |
Non-Operating Income | NA | -0.18 | 0.28 | 0.17 | 0.09 |
Interest Expense | NA | 0.01 | 0.01 | 0.01 | 0.01 |
Pretax Income | NA | -5.15 | -4.43 | -6.60 | -4.11 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.15 | -4.43 | -6.60 | -4.11 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.15 | -4.43 | -6.60 | -4.11 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 0.22 | 0.29 | 0.22 | 0.05 |
Diluted EPS Before Non-Recurring Items | NA | -13.31 | -15.47 | -29.50 | -85.61 |
Diluted Net EPS (GAAP) | NA | 36.33 | -15.47 | -29.50 | -85.61 |